Insider Selling: Pulse Biosciences (NASDAQ:PLSE) CTO Sells 20,000 Shares of Stock

Key Points

• Darrin Uecker, CTO of Pulse Biosciences, sold 20,000 shares at an average price of $16.21, totaling $324,200, which reduced his ownership in the company by 14%.
• Following recent insider sales, Pulse Biosciences' stock saw a 13.8% increase, trading at $18.52 with a market capitalization of $1.25 billion.
• Pulse Biosciences reported earnings of ($0.28) EPS for the last quarter, missing analyst estimates, while the stock has a consensus "Buy" rating with a target price of $22.00.

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) CTO Darrin Uecker sold 20,000 shares of the company's stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $16.21, for a total value of $324,200.00. Following the completion of the transaction, the chief technology officer directly owned 122,872 shares in the company, valued at approximately $1,991,755.12. This trade represents a 14.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Darrin Uecker also recently made the following trade(s):

• On Monday, September 15th, Darrin Uecker sold 25,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $15.77, for a total value of $394,250.00.
• On Thursday, September 11th, Darrin Uecker sold 25,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $14.78, for a total transaction of $369,500.00.

Pulse Biosciences Stock Up 13.8%

PLSE stock traded up $2.25 during mid-day trading on Thursday, hitting $18.52. 547,118 shares of the company were exchanged, compared to its average volume of 181,542. Pulse Biosciences, Inc has a 12-month low of $13.77 and a 12-month high of $25.00. The firm has a market capitalization of $1.25 billion, a P/E ratio of -17.64 and a beta of 1.68. The business has a fifty day simple moving average of $15.54 and a 200-day simple moving average of $16.15.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02).

Institutional Investors Weigh In On Pulse Biosciences

Large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its position in Pulse Biosciences by 0.4% in the 4th quarter. Bank of America Corp DE now owns 788,454 shares of the company's stock valued at $13,727,000 after buying an additional 2,884 shares during the period. Deutsche Bank AG raised its stake in shares of Pulse Biosciences by 65.1% in the fourth quarter. Deutsche Bank AG now owns 16,795 shares of the company's stock valued at $292,000 after acquiring an additional 6,625 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Pulse Biosciences by 14.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,308 shares of the company's stock valued at $667,000 after purchasing an additional 4,773 shares during the period. GAMMA Investing LLC boosted its holdings in Pulse Biosciences by 2,203.1% in the first quarter. GAMMA Investing LLC now owns 6,034 shares of the company's stock valued at $97,000 after purchasing an additional 5,772 shares during the period. Finally, Rhumbline Advisers grew its stake in Pulse Biosciences by 6.3% during the 1st quarter. Rhumbline Advisers now owns 27,375 shares of the company's stock worth $440,000 after purchasing an additional 1,614 shares in the last quarter. 76.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Oppenheimer initiated coverage on Pulse Biosciences in a research note on Monday, July 7th. They set an "outperform" rating and a $22.00 price target on the stock. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $22.00.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.